International Brand Name:
In treatment of:
Management of supraventricular arrhythmias
Congestive heart failure is precipitated or aggravated; Sleep problems; Decreases exercise capacity; Worsens chronic obstructive lung diseases; Gastrointestinal problems; Nausea ,Tiredness, Bradycardia, Rash, Prolonged QT interval, Altered peripheral circulation, Hypotension, Allergic manifestations, Headache, Dizziness
Hypersensitivity to the drug; Second or third degree heart block; Cardiogenic shock; Bradycardia; Chronic obstructive pulmonary diseases; Patient`s with long QT intervals; Right ventricular hypertrophy; Sick sinus syndrome; Alcoholism; General anesthesia; Renal impairment; Upper respiratory infections; Heart failure; Diabetic ketoacidosis
Peripheral arterial diseases ; Congestive heart failure; Renal impairment; Hepatic impairment; Diabetes mellitus; Hypokalemia; Phaeochromocytoma; Anaesthesia; Electrolyte imbalance
Antiarrhythmics such as Disopyramide, Quinidine and Procainamide: Prolong refractoriness. Digoxin: Proarrhythmic events were frequent. Calcium blocking drugs: Additive effects on atrioventricular conduction, hypotension-hence should be used with caution. Reserpine, Guanethidine: Hypotension, marked bradycardia which may produce syncope. Insulin and other antidiabetics: Hyperglycaemia may occur. Symptoms of hypoglycaemia may be masked. Clonidine: Caution advised when discontinuing clonidine since it may lead to rebound hypertension. Salbutamol, Isoprenaline & Terbutaline: Efficacy of these drugs decreased. TCAs, Terfenadine, Astemizole, Phenothiazines: Caution should be observed since these drugs also prolong QT intervals.
80to 160mg/day, increased if required to 320mg/day in arrhythmia & hypertension as single or divided doses. In case of angina dose may be increased up to 360mg/day.Maximum daily dose: 640mg